Zacks Investment Research
06 Feb 2026, 16:50 UTC · 38w ago
Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study
Impact · against what's priced in
Bayer's asundexian shows promising Phase III results with a 26% reduction in recurrent ischemic stroke and a clean safety profile. This provides a concrete catalyst for regulatory filing and commercialization of a potential blockbuster drug.
- BAYRY+0.80
No priced-in read yet
- In context
The successful completion of the Phase III OCEANIC-STROKE study, showing a 26% reduction in recurrent ischemic stroke with no increase in major bleeding, creates a clear path toward regulatory submission and commercialization.
Read from the article alone
Search tags
